Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients

This study reports the effectiveness of three injections of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine in 141 Allo‐HSCT recipients with a median follow‐up of 6 months post‐third shot. We demonstrate a long‐term high protection of Allo‐HSCT recipients since only 2 infections and one death related to COVID‐19 occurred.

Domaines

Sciences du Vivant [q-bio]

Bibliothèque universitaire Nantes Université : Connectez-vous pour contacter le contributeur

https://hal.science/hal-04743368

Soumis le : vendredi 18 octobre 2024-11:52:09

Dernière modification le : dimanche 20 octobre 2024-03:14:17

Dates et versions

hal-04743368 , version 1 (18-10-2024)

Identifiants

HAL Id : hal-04743368 , version 1
DOI : 10.1002/hon.3006
PUBMED : 35468662
PUBMEDCENTRAL : PMC9087413

Citer

Patrice Chevallier, Maxime Jullien, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, et al.. Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients. Hematological Oncology, 2022, 40 (5), pp.1097-1099. ⟨10.1002/hon.3006⟩. ⟨hal-04743368⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS UNIV-ANGERS CRCI2NA NANTES-UNIVERSITE UFR-MEDECINE-NANTES

2 Consultations

0 Téléchargements